epilepsy News
-
Showcase
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
On March 15th 2015, Tim Buckinx’ son said: “Papa, you work in digital, can’t you create a light that turns on when my brain switches off?” At ten years old, he was simply fed up with the daily impact of his refractory epilepsy. That pain became a vision, and that vision became the Belgian digital therapeutics company epihunter, aimed at enabling people with a brain ...
By Epihunter NV
-
Belgian healthtech startup, epihunter, launches second breakthrough for absence epilepsy
“Including video in epileptic seizure detection has the potential to change the way neurologists and epileptologists assess and document seizure frequency and the effect of therapy,” says Dr Sándor Beniczky, Head of Clinical Neurophysiology at the Danish Epilepsy Centre. It is estimated that 1 in 100 people have epilepsy, and 1 in 3 people with epilepsy continue to experience ...
By Epihunter NV
-
Worldwide first absence seizure tracker becomes available to Australian families
More than 250,000 people are living with epilepsy in Australia, of which 1 in 7 are having difficult-to-notice absence seizures. Such seizures are different from tonic-clonic (convulsive) seizures, and are typically shorter in length, with a brief loss of consciousness. Even though this type of seizure usually does not lead to physical injury, it has a major impact on the wellbeing of the person ...
By Epihunter NV
-
Epihunter awarded $200k grant to support the commercialization of its AI seizure detection algorithm
Belgian health tech startup epihunter NV is awarded a $200,000 grant from Epilepsy Foundation to further validate and market their CE labelled epileptic seizure detection algorithm. “The objective seizure data collected by epihunter can help clinicians make more informed treatment decisions,” says Dr Alexander Rotenberg, neurologist at Boston Children’s Hospital and ...
By Epihunter NV
-
ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Neurona Therapeutics on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and ...
-
Belgian healthtech startup, epihunter, launches second breakthrough for absence epilepsy
Belgian startup, epihunter, introduces automated video functionality to their CE-marked seizure detection app - a breakthrough for children and adults with epilepsy, their families and doctors. “Including video in epileptic seizure detection has the potential to change the way neurologists and epileptologists assess and document seizure frequency and the effect of therapy,” says Dr ...
By Epihunter NV
-
Brain Sentinel Announces Launch of SeizureLink, its sEMG-Based Seizure Alerting System, Available Without a Prescription
Brain Sentinel Consumer Systems, LLC (herein “Brain Sentinel”) announces the global launch of its new SeizureLink™ Alerting System at the Epilepsy Foundation’s “2018 Epilepsy Pipeline Conference”, currently being held in San Francisco, CA. Pre-ordering for the U.S. will begin in March 2018, with shipments planned to begin by mid-summer via SeizureLink.com. ...
-
Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, which is being held January 10 -13, 2022. The presentation will ...
-
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of ...
-
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. NRTX-1001 is being evaluated in a Phase 1/2 clinical trial in people with drug-resistant mesial temporal lobe epilepsy. The data are being ...
-
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, which is being organized in partnership with the Harvard Stem Cell Institute, ...
-
Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
-
Brain Sentinel, Inc. Announces the Purchase of IctalCare A/S Assets
Brain Sentinel, Inc., a Texas company, has purchased the assets of IctalCare A/S, a Danish company. These assets include intellectual property, and a non-prescription, wearable device designed to monitor for seizure activity. "We are excited to add to our product line a small, wearable surface electromyography (sEMG) monitor that consumers may order and use without a prescription," said Mike ...
-
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been initiated and will begin recruiting soon Neurona Therapeutics, a clinical-stage biotherapeutics ...
-
NeuroOne Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's Proxy Statement for its Annual Meeting of Stockholders that occurred on ...
-
Wireless EEG for Fast Prep and Easy Use: Q&A with Aswin Gunasekar, CEO of Zeto
Electroencephalography (EEG) devices are incredibly helpful in diagnosing and monitoring certain brain disorders, such as epilepsy and strokes. However, they are not particularly user-friendly or convenient, with specialized technicians performing time consuming procedures, such as skin preparation, to get patients ready to undergo the procedure. A combination of messy gels and wires also makes ...
By Zeto, Inc.
-
Canaquest - Recent developments
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated ...
-
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, ...
-
Natalie Dakers: Chair of Augurex’s Board of Directors Receives 2019 Milton Wong Award
Ms. Dakers began her career in Life Sciences at the University of British Columbia, managing technology transfer for the University Industry Liaison Office (UILO) where she was involved in the creation and spin-off of more than a dozen start-up high-tech and biotech companies. She then went on to co-found NeuroMed Technologies Inc., a private biotechnology company developing drugs for pain, ...
-
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive, external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications, including ADHD, depression, and drug resistant epilepsy. The therapy is the first ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you